ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC"
Episode Synopsis
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.
More episodes of the podcast Two Onc Docs
Hodgkin Lymphoma 2025 UPDATE
24/11/2025
Anal Cancer 2025 UPDATE
17/11/2025
Urothelial ESMO 2025 Updates
10/11/2025
Board Review Tidbits
03/11/2025
Porphyria
27/10/2025
Metastatic Breast Cancer 2025 UPDATE
20/10/2025
Localized Breast Cancer 2025 UPDATE
13/10/2025
In God we trust